Inclusion Criteria:

1. Age ≥ 18 years

2. Histologically or cytologically confirmed, locally advanced or metastatic solid
tumour, relapsed or refractory to standard therapy. Only for the dose-expansion
phase:(i) breast cancer, with FGFR1 amplification with at least one prior endocrine
therapy in the metastatic setting if ER+, and at least one chemotherapy line
otherwise or (ii) tumour progressing after at least one line of treatment with an
antiangiogenic drug (e.g.: sorafenib, sunitinib, bevacizumab) as a single agent or in
a chemotherapy combination

3. One or more lesion suitable for DCE-MRI and for DCE-US evaluation

4. Life expectancy ≥ 3 months

5. Full recovery (to Grade ≤ 1) from any prior surgical procedure(s) and from
reversible side effects of prior therapy for cancer including radiation therapy,
chemotherapy, and immunotherapy

6. Adequate haematologic function (haemoglobin ≥ 9 g/dL, absolute neutrophil count [ANC]
≥ 1500/mL, platelets ≥ 100,000/mL), adequate renal function (serum creatinine < 1.5
mg/dL or creatinine clearance > 40 mL/min), and adequate hepatic function (serum
bilirubin ≤ 1.5 x upper limit of normal (ULN) mg/dL, aspartate aminotransferase (AST)
or alanine aminotransferase (ALT) ≤ 3 x ULN)

7. ECOG performance status ≤ 1

8. Negative serum pregnancy test at screening

9. For men and women of child-bearing potential, use of a medically accepted method of
contraception

Exclusion Criteria:

1. Active central nervous system (CNS) metastases not controlled by prior surgery or
radiotherapy and/or low dose steroids

2. Haematologic malignancies (including leukaemia of any form, lymphoma, and multiple
myeloma)

3. Active second malignancy or history of another malignancy within 2 years, with the
exception of non-melanoma skin cancers or carcinoma in situ (CIS) of the breast or
cervix or controlled, superficial carcinoma of the bladder

4. Treatment with any anticancer agent within 3 weeks, including investigational agents,
chemotherapy, immunotherapy, biologic or hormonal therapy, surgery or radiation
therapy (6 weeks for nitrosoureas, mitomycin or bevacizumab); luteinizing hormone
releasing hormone (LHRH) agonist for prostate and mitotane for adrenal carcinoma are
allowed.

5. Significant cardiovascular disease or condition including: congestive heart failure,
ventricular and/or supra-ventricular arrhythmia, severe conduction disturbance
(including QTc interval prolongation > 0.47 sec), history of severe arrhythmia, or
history of familial arrhythmia, angina pectoris, LVEF < 50%, uncontrolled
hypertension (systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥
90 mm Hg with optimized antihypertensive therapy), myocardial infarction within 6
months prior to administration of the first dose, > Class I cardiovascular disease
according to the NYHA Functional Criteria

6. Ongoing treatment with Warfarin

7. Unavoidable concomitant treatment with any drug known for potential risk of causing
Torsades de Points

8. Significant gastrointestinal abnormalities, including ulcerative colitis, chronic
diarrhoea associated with intestinal malabsorption, Crohn's disease, and/or prior
surgical procedures affecting absorption or requirement for intravenous (IV)
alimentation

9. Known pre-existing clinically significant disorder of the hypothalamic-pituitary
axis, thyroid and adrenal gland

10. Serious/active bacterial, viral or fungal infection (including known active human
immunodeficiency virus [HIV] infection) requiring systemic treatment

11. Concurrent severe or uncontrolled medical disease or organ system dysfunction which,
in the opinion of the Investigators, would limit life expectancy to < 3 months,
compromise the patient's safety, or interfere with evaluation of the safety of the
investigational product

12. Psychiatric disorder or altered mental status that would preclude understanding of
the informed consent process and/or completion of the necessary study procedures